Literature DB >> 8681296

Pancreatic carcinoma in perspective. A continuing challenge.

H J Wanebo1, M P Vezeridis.   

Abstract

There are approximately 27,000 new cases of carcinoma of the pancreas each year and most afflicted patients will die of the disease. Although smoking is a common denominator, chronic pancreatitis is considered an important precursor lesion in a smaller number of cancers. Pancreatic cancer is primarily a disease of the pancreatic ducts. The molecular events are under intense study, but c-K-ras mutation is involved in approximately 80% of the cases and p53 to a slightly lesser degree (60-80%). Early manifestations are usually occult, but jaundice is a common manifestation in patients with cancers of the pancreatic head. Thin-slice computed tomography, portography, and endoscopic retrograde cholangiopancreatography are currently the most sensitive detection techniques. The developing use of endoscopic ultrasound and laparoscopy appear to enhance detection and are under evaluation. In many patients with advanced disease, endoscopic bypass may eliminate the need for unnecessary surgery, although gastrointestinal bypass is still required in some patients (10-15%). Curative resection is possible in selected patients (perhaps 10-15%), with expectation of extended survival ranging from 6->20% in some series. The survival differences may be related to stage, patient selection, and the expertise of the operative team. Preoperative chemotherapy/radiation is under study and may improve outcome. Clinical trial participation is essential for improvement in treatment outcomes.

Entities:  

Mesh:

Year:  1996        PMID: 8681296     DOI: 10.1002/(SICI)1097-0142(19960801)78:3<580::AID-CNCR38>3.0.CO;2-T

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Safety of pancreatic surgery in a small DGH.

Authors:  H M Kocher; S Gupta
Journal:  Ann R Coll Surg Engl       Date:  2000-01       Impact factor: 1.891

2.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models.

Authors:  M Bouvet; M Yang; S Nardin; X Wang; P Jiang; E Baranov; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses.

Authors:  M Voss; P Hammel; G Molas; L Palazzo; A Dancour; D O'Toole; B Terris; C Degott; P Bernades; P Ruszniewski
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

5.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

6.  Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice.

Authors:  J Tepel; O Dagvadorj; M Kapischke; B Sipos; A Leins; B Kremer; H Kalthoff
Journal:  Int J Colorectal Dis       Date:  2005-08-16       Impact factor: 2.571

7.  Pancreatic cancer and fibrinogen storage disease.

Authors:  J M Radhi; B E Lukie
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

8.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

9.  Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers.

Authors:  Koh Furugaki; Toshiki Iwai; Kumiko Kondoh; Yoichiro Moriya; Kazushige Mori
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

10.  Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells.

Authors:  S T Lau; Z X Lin; P S Leung
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.